title: Enhancing effects of oral adjuvants on anti-HBs responses induced by hepatitis B vaccine.
abstract: Hepatitis B (HB) vaccine is very promising for the prevention of HB infection. There exist, however, some non-responders to current vaccination trials. In this study, taurine, parotin and lithium were selected as adjuvants which can be administered orally. The mechanisms of these three materials as adjuvants and their effects on HB vaccine were investigated in mice. For instance, taurine induced polyclonal antibody production and exhibited adjuvant activity. Although taurine did not have any activity on the proliferation of thymocytes nor stimulate IL-2 production, taurine did induce IL-1 production by macrophages. It was considered that taurine-induced IL-1 would play an essential role in the proliferation and differentiation of B cells. Parotin also induced polyclonal antibody production and exhibited adjuvant activity. These effects of parotin were not affected even if macrophages or T cells were depleted, and parotin itself had an IL-1-like activity. Therefore, it was considered that parotin acted directly on B cells by its IL-1-like activity and mitogenic activity, resulting in the proliferation and differentiation of B cells. Lithium induced neither polyclonal antibody production, nor IL-1 or IL-2 production. However, when given with an antigen, lithium activated the humoral immune system, resulting in the augmentation of antibody production. Oral administration of taurine, parotin and lithium were capable of restoring antibody responses to HB surface antigen (HBsAg) in HBsAg-nonresponder mice. Furthermore, taurine, parotin and lithium enhanced the adjuvant effects of aluminium contained in the present HB vaccine. These observations indicate that use of these oral adjuvants may open new perspectives in the field of human HB vaccination.
authors.affiliation: 3rd Department of Internal Medicine, Nara Medical University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kuriyama
authors.forename: T
authors.initials: T
authors.lastname: Tsujii
authors.forename: S
authors.initials: S
authors.lastname: Ishizaka
authors.forename: E
authors.initials: E
authors.lastname: Kikuchi
authors.forename: K
authors.initials: K
authors.lastname: Kinoshita
authors.forename: K
authors.initials: K
authors.lastname: Nishimura
authors.forename: K
authors.initials: K
authors.lastname: Kitagami
authors.forename: M
authors.initials: M
authors.lastname: Yoshikawa
authors.forename: M
authors.initials: M
authors.lastname: Matsumoto
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D006509:Hepatitis B / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis*; D008094:Lithium / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D008815:Mice, Inbred Strains; D012471:Salivary Proteins and Peptides / Q000276:immunology; D013654:Taurine / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D006510:Hepatitis B Antibodies; D012471:Salivary Proteins and Peptides; D014761:Viral Hepatitis Vaccines; D013654:Taurine; D008094:Lithium